

Teva is Creating a **Healthy Future**

Healthy Future, Teva's sustainability strategy, guides how we care for people, the planet and our business—because they are all connected. Addressing global challenges and supporting our communities, while ensuring our business success, allows us to continue providing medicines to the millions of patients around the world who count on us.

We hold ourselves accountable.



Meeting or exceeding bold targets and setting the bar higher with new ones



largest issuer of sustainability-linked bonds in the pharma sector and second largest in the world (total issuance: \$7.5B), connecting sustainability commitments and progress to our business strategy





People



530Mdoses of medicine donated to people in need

= 10M doses



access to medicines programs launched, providing treatments to underserved populations (of 8 committed by 2025)*



\$40.9B in savings from Teva's generic medicines across 20 countries



49% of management positions held by women





Planet



1 of first 2 companies to receive the product-level British Standards Institution (BSI) certification for **responsible manufacturing practices** that minimize antimicrobial resistance risk



Active member of the Pharmaceutical Supply Chain Initiative (PSCI), a coalition of pharmaceutical and healthcare companies that share a vision of better social, environmental and economic outcomes



A- Climate score and B Water score from



CDP, a non-profit that helps companies disclose environmental impact



GHG emissions near-term reduction targets (scope 1, 2 and 3) **validated by Science Based Targets initiative (SBTi)**



Performance, Credibility, Transparency





Global Environment, Health and Safety Management System **aligned with international standards,** including ISO 14001, 45001 and EMAS



43% of Teva's electricity comes from renewable sources, targeting 100% by 2035



reduction in scope 1 and 2 greenhouse gas (GHG) emissions (vs. 2019), exceeding our 2025 target two years ahead of schedule

12%
reduction in scope 3
GHG emissions (vs. 2020),
tracking strongly against
our 2030 target



Aim to achieve **net zero** emissions by 2045





Business

94% of employees are

of employees are comfortable reporting misconduct, 11% more than benchmarked companies



of targeted active employees participated in compliance and

ethics trainings





3%

in our industry in **EcoVadis** sustainable procurement assessment



Our progress is being recognized.

Improved score in 4 key ESG ratings

(vs. 2022) MSCI, Sustainalytics, ISS, EcoVadis

Best Healthcare Company for Sustainability Reporting

from ESG Investing Awards

Corporate Social Responsibility Initiative of the Year

from Global Generics and Biosimilars Awards